Anorexia: Clinical Trials

155 trials for Anorexia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

93 completed, 18 unknown, 10 not yet recruiting, 9 active not recruiting. 51 Not applicable, 43 Phase 2, 28 Phase 3, 14 Phase 1, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable51Completed 33, Unknown 6, Not yet recruiting 4, Withdrawn 3, Active not recruiting 2, Terminated 2, Recruiting 1
Phase 243Completed 21, Terminated 5, Unknown 5, Active not recruiting 3, Not yet recruiting 3, Recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 328Completed 14, Unknown 5, Recruiting 3, Active not recruiting 2, Not yet recruiting 2, Terminated 2
Phase 114Completed 8, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 42Completed 2
Early Phase 11Active not recruiting 1

Follow Anorexia: new trials by email Literature Review of Anorexia trials Research Report on Anorexia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa
Donepezil - Anorexia Nervosa
Phase 2Not yet recruitingNew York State Psychiatric Institute102027-01-012026-10-23
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
Rilogrotug, Placebo - Cachexia; Cancer, Cachexia
Phase 2 / Phase 3Not yet recruitingAVEO Pharmaceuticals, Inc.9502026-11-012026-10-28
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
ponsegromab, placebo - Non-small Cell Lung Cancer (NSCLC), Cachexia
Phase 1Not yet recruitingPfizer802026-10-232026-09-25
Effects of Synbiotic Supplementation on Gastrointestinal Symptoms, Appetite, and Nutritional Recovery in Patients After Autologous Bone Marrow Transplant
Tri-component Synbiotic Supplement - Hematologic Neoplasms, Gastrointestinal Symptoms
Not applicableNot yet recruitingAlexandria University402026-10-012026-10-01
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
Nanocrystalline Megestrol Acetate Oral Suspension, Placebo - Nasopharyngeal Cancinoma (NPC)
Phase 3RecruitingSun Yat-sen University2042026-09-292026-10-15
Study on the Prevention of Weight Loss Through Physical Activity Among Nursing Home Residents
Physical activity, Appetite assessment, Food intake assessment - Appetite Loss in Aging, Anorexia of Aging
Not applicableNot yet recruitingUniversity Hospital, Toulouse5962026-09-012026-09-21
Pediatric Prolonged-Release Melatonin for Sleep Disturbances in Children and Adolescents With Anorexia Nervosa (MELSom-ANOREXIA)
Pediatric Prolonged-Released Melatonin (PedPRM), Placebo - Anorexia Nervosa, Sleep Disorders in Children
Phase 3Not yet recruitingAssistance Publique Hopitaux De Marseille1202026-09-012026-05-08
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Nanocrystalline megestrol acetate, Placebo - Hepatocellular Carcinoma (HCC), Cachexia
Phase 2Not yet recruitingNanfang Hospital, Southern Medical University882026-06-222026-05-04
Fecal Microbiota Transplant for Anorexia Nervosa
Fecal Microbiota Transplant, Placebo - Anorexia Nervosa Restricting Type, Anorexia Nervosa
Not applicableNot yet recruitingHamilton Health Sciences Corporation202026-06-012026-05-27
Visugromab in Cachexia International Trial
Visugromab (CTL-002), Placebo - Cancer-associated Cachexia
Phase 2 / Phase 3RecruitingCatalYm GmbH5182026-04-162026-09-22
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2 / Phase 3RecruitingPfizer9822025-10-032026-10-14
Biolizin for Improving Functional Poor Appetite in Children Aged 6 to 36 Months (CTBE2502)
Biolizin, Standardized caregiver counseling on responsive feeding - Feeding and Eating Disorders of Childhood, Appetite Disorders
Not applicableRecruitingHaiphong University of Medicine and Pharmacy1102025-09-202026-01-30
The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash
Routine Protective Oral Care, Protective Oral Care Using Peppermint Oil Mouthwash - Hematologic Neoplasms, Nausea
Not applicableNot yet recruitingŞule Güzle722025-09-102025-09-17
Ketamine Effects on Learning In Eating Disorders
Ketamine infusion - Anorexia Nervosa, Atypical Anorexia Nervosa
Phase 2Enrolling by invitationAmanda Downey, MD202025-06-052026-10-13
A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms
Danning Tablet - Indigestion, Dyspepsia
RecruitingShanghai Hutchison Pharmaceuticals Limited45002025-04-302025-05-14
Effectiveness of Hatha Yoga and From Feeling to Seeing the Body (FSB) in Female Adolescents and Young Adults With Eating Disorders.
Hatha Yoga Group (Y), From Feeling to Seeing the Body Group (FSB), Control Group (C) - Body Image, Eating Disorders
Not applicableCompletedAzienda Ulss 2 Marca Trevigiana542025-03-102026-04-06
Insights Into Participating in Clinical Studies for Anorexia
Anorexia
Not yet recruitingPower Life Sciences Inc.5002024-12-012023-11-24
Effectiveness of Cyproheptadine Hydrochloride Against Appetite to Improve Children's Nutritional Status
cyproheptadine hydrochloride, Giving placebo divided by 2 dose every 12 hours for 4 weeks. - Appetite Loss
Not applicableCompletedUniversitas Indonesia442024-11-042025-06-10
Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects
ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg - Obesity; Overweight
Phase 2CompletedRose Pharma Inc402024-09-262026-06-01
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma
Phase 2RecruitingOHSU Knight Cancer Institute662024-07-172026-07-16

Showing 20 of 155. Sign in to see all of them.

Narrower conditions

Cachexia (44)  ·  Weight Loss (30)  ·  Anorexia Nervosa (28)  ·  Neoplasms (20)  ·  Feeding and Eating Disorders (17)  ·  Carcinoma, Non-Small-Cell Lung (16)  ·  Malnutrition (14)  ·  Fatigue (13)  ·  Nausea (11)  ·  Pancreatic Neoplasms (11)  ·  Pain (9)  ·  Bulimia (8)  ·  Lung Neoplasms (8)  ·  Obesity (7)

Broader conditions

Pathological Conditions, Signs and Symptoms (155)  ·  Signs and Symptoms, Digestive (155)  ·  Signs and Symptoms (153)  ·  Body Weight (58)  ·  Body Weight Changes (55)  ·  Mental Disorders (45)  ·  Thinness (44)  ·  Neoplasms by Site (33)  ·  Weight Loss (28)  ·  Nutritional and Metabolic Diseases (24)  ·  Neoplasms (23)  ·  Nutrition Disorders (23)  ·  Digestive System Diseases (22)  ·  Respiratory Tract Diseases (22)  ·  Neurologic Manifestations (20)

Interventions

Megestrol Acetate (15)  ·  Mirtazapine (5)  ·  Olanzapine (5)  ·  Exercise (3)  ·  Transcranial Magnetic Stimulation (3)  ·  Dosage Forms (2)  ·  Infliximab (2)  ·  Watchful Waiting (2)  ·  anamorelin (2)  ·  lorcaserin (2)  ·  nabiximols (2)  ·  Acupuncture Therapy (1)  ·  Aftercare (1)  ·  Aromatherapy (1)  ·  Ascorbic Acid (1)

Sponsors

M.D. Anderson Cancer Center (8)  ·  Pfizer (5)  ·  Alliance for Clinical Trials in Oncology (4)  ·  University College Dublin (4)  ·  Bristol-Myers Squibb (3)  ·  Mayo Clinic (3)  ·  University of Minnesota (3)  ·  Wake Forest University Health Sciences (3)  ·  Centre Hospitalier Universitaire de Nice (2)  ·  DiaSorin Inc. (2)  ·  Eisai Inc. (2)  ·  Fondation Lenval (2)  ·  Instituto Nacional de Cancerologia de Mexico (2)  ·  New York State Psychiatric Institute (2)  ·  Par Pharmaceutical, Inc. (2)

Countries

United States (65)  ·  France (14)  ·  China (11)  ·  Italy (11)  ·  Canada (8)  ·  Germany (6)  ·  Vietnam (6)  ·  Taiwan (5)  ·  United Kingdom (5)  ·  Brazil (4)  ·  Ireland (4)  ·  Israel (4)  ·  Spain (4)  ·  Australia (3)  ·  Bulgaria (3)

Top investigators

Aminah Jatoi, MD (6)  ·  Lynn D Kramer, MD (2)  ·  Agop Y. Bedikian, MD (1)  ·  Alessandro Laviano, MD (1)  ·  Alexander Ginting (1)  ·  Amanda E. Downey, MD (1)  ·  Ana Pablos Monzo, PhD (1)  ·  Andrea Ardizzoni, MD (1)  ·  Andreas Karwautz, Univ.-Prof. (1)  ·  Andrew M Lee, MD, PhD (1)  ·  Anh D Dang, PhD (1)

Results publications

PMID 21343383, PMID 36999619, PMID 11428126, PMID 11527676, PMID 11607047, PMID 11786587, PMID 12457271, PMID 12648025, PMID 15197210, PMID 15778874, PMID 15857739, PMID 16317825, PMID 16376734, PMID 16408219, PMID 1666930, PMID 16849753, PMID 17566383, PMID 17589370, PMID 17674351, PMID 17685872, PMID 18257397, PMID 18402303, PMID 18728826, PMID 19057523, PMID 19587829, PMID 19665818, PMID 1977637, PMID 19883531, PMID 19896326, PMID 20076976, PMID 21993434, PMID 22076835, PMID 22520120, PMID 23006802, PMID 23141881, PMID 23439759, PMID 24257035, PMID 24513422, PMID 25524795, PMID 26132687, PMID 26646758, PMID 26810442, PMID 26883879, PMID 27403414, PMID 28827942, PMID 29325236, PMID 29472176, PMID 29550881, PMID 29971962, PMID 32116856

NIH funding

2023 (1), 2025 (1), F31MH096433 (1), KL2TR001870 (1), P30CA012197 (1), P30CA015083 (1), P30CA069533 (1), P30MH066386 (1), R01MH070620 (1), R01MH110538 (1), R34MH123596 (1), UG1CA189823 (1)